-PTI "Discrimination" against Muslims is giving rise to a feeling of injustice among them, Press Council Chairman Markanedya Katju on Sunday claimed and rebuked the media for what he described as "demonising" Muslim community through "irresponsible" journalism. "Whenever a bomb blast occurs or such incident takes place, within an hour or so many TV channels start showing that an email or sms has come from the Indian Mujahideen, JeM or Harkatuljihad-e-Islam, or...

-Live Mint CCEA clears recommendations on sugar sector made by Rangarajan panel; subsidy burden to rise Pushing ahead with long-pending reforms of the sugar industry, the cabinet on Thursday approved the dismantling of rules requiring sugar mills to sell the sweetener at below-market prices through the public distribution system (PDS) and abolished curbs on open market sale. The cabinet committee on economic affairs cleared the recommendations made by a panel headed by C....

-The Indian Express India is no insecure dictatorship junking international obligations for cheap populism. The highest court of the world's largest democracy has made a nuanced distinction between real innovation and marketing gimmickry. Yet, the Swiss pharmaceutical giant Novartis's response to the recent Supreme Court verdict in Novartis vs Union of India has been imperial in tone. The judgment "discourages innovative drug discovery", it claimed. It accused Indian law of lagging...

-The Business Standard Interview with Founder chairman of Cancer Patients Aid Association Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting. Sapru, founder chairman of Cancer Patients Aid Association, or CPAA (which moved the Supreme Court to keep the prices of the cancer drug low), tells Sushmi Dey what the judgment means to cancer patients....

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...